Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Carcinoma of the Breast

Interventions: Drug: Paclitaxel
Drug: Trastuzumab

First Posted Date: 2007-10-11

Last Posted Date: 2024-06-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 406

Registration Number: NCT00542451

Locations: 🇺🇸
Case Western University, Cleveland, Ohio, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 17 locations

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Carcinoma

Interventions: Drug: Albumin-bound paclitaxel
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2007-10-08

Last Posted Date: 2019-10-29

Lead Sponsor: Celgene

Target Recruit Count: 1052

Registration Number: NCT00540514

Locations: 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸
Robert A. Moss, MD, FACP, Inc., Fountain Valley, California, United States
🇺🇸
Mercy Hospital, Portland, Maine, United States

and more 34 locations

Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Paclitaxel
Drug: AZD2171
Drug: Carboplatin

First Posted Date: 2007-10-04

Last Posted Date: 2011-06-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 6

Registration Number: NCT00539331

Locations: 🇯🇵
Research Site, Tokyo, Japan

Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer

Terminated

Conditions: Breast Cancer

Interventions: Procedure: Core Biopsy
Procedure: Blood Collection
Drug: Paclitaxel
Drug: Avastin

First Posted Date: 2007-09-28

Last Posted Date: 2017-01-25

Lead Sponsor: Hoosier Cancer Research Network

Target Recruit Count: 11

Registration Number: NCT00537173

Locations: 🇺🇸
Horizon Oncology Center, Lafayette, Indiana, United States
🇺🇸
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Baylor College of Medicine - Methodist Breast Center, Houston, Texas, United States

and more 1 locations

Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Enzastaurin
Drug: Bevacizumab
Drug: Placebo
Drug: Paclitaxel

First Posted Date: 2007-09-28

Last Posted Date: 2020-09-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2

Registration Number: NCT00536939

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Phase 1

Completed

Conditions: Adult Solid Neoplasm
BRCA1 Mutation Carrier
BRCA2 Mutation Carrier
Hereditary Breast and Ovarian Cancer Syndrome

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2007-09-26

Last Posted Date: 2015-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 107

Registration Number: NCT00535119

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 4 locations

Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

Phase 2

Conditions: Breast Cancer

First Posted Date: 2007-09-24

Last Posted Date: 2013-08-26

Lead Sponsor: Instituto Nacional de Cancerologia, Columbia

Target Recruit Count: 160

Registration Number: NCT00533936

Locations: 🇲🇽
Instituto Nacional de Cancerologia, Mexico City, Distrito Federal, Mexico
🇲🇽
Hospital General de Mexico, Mexico City, Distrito Federal, Mexico

High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 3

Completed

Conditions: Lung Cancer
Radiation Toxicity

Interventions: Biological: Cetuximab
Drug: Carboplatin
Drug: Paclitaxel
Radiation: 60 Gy RT
Radiation: 74 Gy RT

First Posted Date: 2007-09-24

Last Posted Date: 2022-06-21

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 544

Registration Number: NCT00533949

Locations: 🇺🇸
Shore Regional Cancer Center at Memorial Hospital - Easton, Easton, Maryland, United States
🇺🇸
CCOP - Christiana Care Health Services, Newark, Delaware, United States
🇺🇸
Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise, Idaho, United States

and more 210 locations